Latest Breast Cancer Trial News from ASCO 2023
We have gathered the most important breast cancer trial updates from the American Society for Clinical Oncology (ASCO) 2023 meeting last month. Here are some of the most significant developments:
CDK4/6 Inhibitors
Several trials have shown promising results for CDK4/6 inhibitors. One trial called NATALEE found that ribociclib can reduce the risk of cancer recurring in patients with early-stage HR-positive/HER2-negative breast cancer. Another trial, called monarchE, showed that abemaciclib, when combined with hormonal therapy, can benefit breast cancer patients over a wide age range. However, it’s important for older patients to be cautious when considering these treatments due to the potential side effects. The SONIA trial suggests that CDK4/6 inhibitors may not always be the best first-line treatment; it is therefore very important to consider individual patient factors.
Antibody-Drug Conjugates (ADCs)
Exciting progress is being made with antibody-drug conjugates. These are substances that consist of a monoclonal antibody that is chemically linked to a drug. One study focused on sacituzumab govitecan (SG), which appears to be both effective and safe in treating metastatic HR-positive/HER2-negative breast cancer, especially for patients with limited treatment options. Another study explored a new ADC called HER3-T-DXd. This targets HER3, a protein that is overexpressed in approximately 30% to 50% of breast cancers. This treatment shows promise for patients with estrogen receptor (ER)-positive or triple-negative metastatic breast cancer who have already received multiple treatments.
Sequential ADC Treatments
Researchers are also studying the order in which ADC treatments should be given to breast cancer patients. By optimizing the treatment sequence, they hope to minimize resistance and improve outcomes. Different ADCs are being evaluated in specific sequences to understand their benefits and effectiveness.
Other Noteworthy Breast Cancer Trial News
The PHERGAIN trial introduces a novel approach that uses early PET scans to determine if HER2-positive breast cancer patients can avoid chemotherapy. The X-7/7 study suggests a new strategy for oral chemotherapy using capecitabine, which reduces side effects while maintaining similar survival rates. Additionally, the CAPItello-291 trial provides updates on the effectiveness and manageable side effects of capivasertib, a potential new AKT inhibitor. AKT receptors regulate the hallmarks of cancer, including tumor growth, survival and the invasiveness of tumor cells.
The ASCO 2023 meeting showcased significant advancements in breast cancer clinical trials and shed light on several potential new treatment options. We will continue to closely follow these trials and provide you with the latest updates as they are released. In the meantime, you can also access the top oncology research from ASCO meetings here.
